<DOC>
	<DOCNO>NCT02026388</DOCNO>
	<brief_summary>This study do obtain sample patient primary hyperoxaluria , cystinuria , adenine phosphoribosyl transferase ( APRT ) deficiency , Dent disease , family member , use future research .</brief_summary>
	<brief_title>Rare Kidney Stone Consortium Biobank</brief_title>
	<detailed_description>Biologic sample store biobank well characterized patient primary hyperoxaluria , cystinuria , APRT deficiency , Dent disease , family member , use future research . This help advance understanding disease expression factor associate kidney injury four diseases overall goal develop new treatment preserve kidney function reduce nephrocalcinosis stone formation .</detailed_description>
	<mesh_term>Kidney Calculi</mesh_term>
	<mesh_term>Nephrolithiasis</mesh_term>
	<mesh_term>Hyperoxaluria , Primary</mesh_term>
	<mesh_term>Cystinuria</mesh_term>
	<mesh_term>Dent Disease</mesh_term>
	<criteria>Diagnosis primary hyperoxaluria ( PH ) meet one follow criterion : 1 . Liver biopsy document alanineglyoxylate aminotransferase ( AGT ) activity normal reference range confirm PH type 1 OR Liver biopsy document glyoxylate reductase/hydroxypyruvate reductase ( GR/HPR ) activity normal reference range confirm PH type 2 2 . Molecular genetic analysis ( DNA test ) confirm mutation know cause PH type 1 , PH type 2 , PH type 3 3 . Urinary oxalate excretion great 0.8 mmol/1.73 m2/day ( &gt; 70 mg/1.73 m2/day ) absence identifiable cause secondary hyperoxaluria , include gastrointestinal disease know cause enteric hyperoxaluria 4 . A patient end stage kidney failure , neither liver biopsy mutational analysis available must : ( ) A plasma oxalate concentration great 60 umol/L kidney biopsy confirm extensive oxalate deposit OR ( b ) Evidence systemic oxalosis 5 . Participants previous protocol `` Tissue Bank Urine , Blood , Tissue Samples Collected Patients Primary Hyperoxaluria '' 'Mayo IRB # ' # 8004 . They already consent bank sample consent serve enroll study . Diagnosis Dent disease meet one follow criterion : 1 . Identified mutation gene encodes chloride exchange transporter 5 ( CLCN5 ) 2 . Low molecular weight proteinuria hypercalciuria 3 . Low molecular weight proteinuria nephrocalcinosis Diagnosis APRT disease meet one follow criterion : 1 . Suspected dihydroxyadeninuria absent APRT enzyme activity measure red blood cell ( RBCs ) . 2 . Homozygosity , compound heterozygosity , know diseasecausing APRT mutation . 3 . Passage dihydroxyadenine stone ( confirm stone analysis ) . Diagnosis Cystinuria meet one follow criterion : 1 . Stone analysis demonstrate stone contain cystine 2 . Increased urinary cystine excretion ( &gt; 250 mg/gm creatinine ) Relative someone confirm primary hyperoxaluria , Dent disease , APRT deficiency ( also know dihydroxyadeninuria ) , cystinuria 1 . Stone former meet inclusion criterion primary hyperoxaluria , cystinuria , Dent disease , APRT deficiency . 2 . Unwilling unable provide consent/assent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>PH</keyword>
	<keyword>primary hyperoxaluria</keyword>
	<keyword>hyperoxaluria</keyword>
	<keyword>primary oxalosis</keyword>
	<keyword>Primary Hyperoxaluria Type 1</keyword>
	<keyword>Primary Hyperoxaluria Type 2</keyword>
	<keyword>Primary Hyperoxaluria Type 3</keyword>
	<keyword>Dent</keyword>
	<keyword>Dents</keyword>
	<keyword>Dent Disease</keyword>
	<keyword>Dent 1</keyword>
	<keyword>Dent 2</keyword>
	<keyword>Cystinuria</keyword>
	<keyword>APRT</keyword>
	<keyword>APRT deficiency</keyword>
	<keyword>Biobank</keyword>
</DOC>